OBJECTIVES: Women with a BRCA1 or BRCA2 mutation are recommended to undergo prophylactic (or risk reducing) bilateral salpingo-oophorectomy (BSO) before age 40, resulting in surgical menopause. Given the concerns of estrogen deprivation on overall health, hormone therapy (HT) is often discussed, yet safety concerns persist. MATERIALS AND METHODS: We performed a systematic literature review of the safety of HT in women with a BRCA mutation undergoing prophylactic BSO. RESULTS: Although there remains a paucity of data on this topic, as evidenced by this systematic review of the contemporary literature, these patients do benefit from treatment, especially as it relates to menopausal symptoms without an apparently increased risk of breast cancer. CONCLUSIONS: Decisions regarding the use of HT in women who undergo BSO after detection of a BRCA mutation must be individualized based on careful consideration of the risks and benefits. However, the risks of a subsequent cancer diagnosis appear small, particularly in regards to the benefits of treatment afforded by HT.
OBJECTIVES:Women with a BRCA1 or BRCA2 mutation are recommended to undergo prophylactic (or risk reducing) bilateral salpingo-oophorectomy (BSO) before age 40, resulting in surgical menopause. Given the concerns of estrogen deprivation on overall health, hormone therapy (HT) is often discussed, yet safety concerns persist. MATERIALS AND METHODS: We performed a systematic literature review of the safety of HT in women with a BRCA mutation undergoing prophylactic BSO. RESULTS: Although there remains a paucity of data on this topic, as evidenced by this systematic review of the contemporary literature, these patients do benefit from treatment, especially as it relates to menopausal symptoms without an apparently increased risk of breast cancer. CONCLUSIONS: Decisions regarding the use of HT in women who undergo BSO after detection of a BRCA mutation must be individualized based on careful consideration of the risks and benefits. However, the risks of a subsequent cancer diagnosis appear small, particularly in regards to the benefits of treatment afforded by HT.
Authors: Stephanie Kearton; Karen Wills; Michael Bunting; Penny Blomfield; Paul A James; Jo Burke Journal: Fam Cancer Date: 2018-07 Impact factor: 2.375
Authors: Jessica L Chan; Suneeta Senapati; Lauren N C Johnson; Laura DiGiovanni; Chan Voong; Samantha F Butts; Susan M Domchek Journal: Menopause Date: 2019-02 Impact factor: 2.953
Authors: Kathryn A Mills; Tanvi V Joshi; Lindsay West; Michelle Kuznicki; Laura Kent; Alexis N Hokenstad; James C Cripe; Candice Woolfolk; Leigha Senter; Jamie N Bakkum-Gamez; Robert M Wenham; David E Cohn; Victoria Bae-Jump; Premal H Thaker Journal: Gynecol Oncol Date: 2020-03-03 Impact factor: 5.482